Cargando…

The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

OBJECTIVE: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasbek, Zekiye, Doğan, Ömer Tamer, Sarı, İsmail, Yücel, Birsen, Şeker, Mehmet Metin, Turgut, Bülent, Berk, Serdar, Siliğ, Yavuz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100081/
https://www.ncbi.nlm.nih.gov/pubmed/27751972
http://dx.doi.org/10.4274/mirt.97269
_version_ 1782466064298278912
author Hasbek, Zekiye
Doğan, Ömer Tamer
Sarı, İsmail
Yücel, Birsen
Şeker, Mehmet Metin
Turgut, Bülent
Berk, Serdar
Siliğ, Yavuz
author_facet Hasbek, Zekiye
Doğan, Ömer Tamer
Sarı, İsmail
Yücel, Birsen
Şeker, Mehmet Metin
Turgut, Bülent
Berk, Serdar
Siliğ, Yavuz
author_sort Hasbek, Zekiye
collection PubMed
description OBJECTIVE: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUV(max)), SUV(av)e, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. METHODS: Serum anti-p53 Ab level was studied in three groups. Patients who underwent (18)F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent (18)F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. RESULTS: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUV(max), SUV(ave), TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05). CONCLUSION: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion.
format Online
Article
Text
id pubmed-5100081
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-51000812016-11-14 The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer Hasbek, Zekiye Doğan, Ömer Tamer Sarı, İsmail Yücel, Birsen Şeker, Mehmet Metin Turgut, Bülent Berk, Serdar Siliğ, Yavuz Mol Imaging Radionucl Ther Original Article OBJECTIVE: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUV(max)), SUV(av)e, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. METHODS: Serum anti-p53 Ab level was studied in three groups. Patients who underwent (18)F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent (18)F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. RESULTS: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUV(max), SUV(ave), TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05). CONCLUSION: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion. Galenos Publishing 2016-10 2016-09-29 /pmc/articles/PMC5100081/ /pubmed/27751972 http://dx.doi.org/10.4274/mirt.97269 Text en © Molecular Imaging and Radionuclide Therapy, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hasbek, Zekiye
Doğan, Ömer Tamer
Sarı, İsmail
Yücel, Birsen
Şeker, Mehmet Metin
Turgut, Bülent
Berk, Serdar
Siliğ, Yavuz
The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
title The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
title_full The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
title_fullStr The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
title_full_unstemmed The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
title_short The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
title_sort diagnostic value of the correlation between serum anti-p53 antibody and positron emission tomography parameters in lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100081/
https://www.ncbi.nlm.nih.gov/pubmed/27751972
http://dx.doi.org/10.4274/mirt.97269
work_keys_str_mv AT hasbekzekiye thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT doganomertamer thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT sarıismail thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT yucelbirsen thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT sekermehmetmetin thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT turgutbulent thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT berkserdar thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT siligyavuz thediagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT hasbekzekiye diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT doganomertamer diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT sarıismail diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT yucelbirsen diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT sekermehmetmetin diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT turgutbulent diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT berkserdar diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer
AT siligyavuz diagnosticvalueofthecorrelationbetweenserumantip53antibodyandpositronemissiontomographyparametersinlungcancer